Article

Quantel Medical debuts IPL system for dry eye treatment

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical's C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical's C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Quantel Medical today announced the launch of its C.STIM IPL system, based on intense pulsed light technology for the treatment of dry eye disease.

Dry eye is a huge public health problem affecting more than 700 million people in the word and it is the most common pathology in ophthalmic visits. Dry eye treatment is now a key question in many specialties like glaucoma, refractive & cataract surgeries, contact lenses and others.

The company pointed out in a news release that the IPL system treats the root causes of dry eyes: Meibomian gland dysfunction, inflammation, and Demodex, to stop the vicious cycle of dry eye.

According to Delphine Southon, dry eye product manager, C.STIM, the platform offers clinical efficacy and patient comfort.

C.STIM has been designed with the aim of combining cutting-edge technology with a sleek, robust and ergonomic design. The device integrates the best technological features to guarantee efficacy, safety, ergonomics and to offer a “plug and play” product easy delegable.

“Drawing on Quantel Medical’s years of experience in intense pulsed light in dermatology, we have now developed an IPL device exclusively for use in ophthalmology designed and manufactured by the Lumibird Medical Group, said said Jean-Marc Gendre, CEO of Lumibird Medical.

Gendre said the product will offer a therapeutic solution to ophthalmologists to treat patients with dry eye disease.

According to the news release, Quantel Medical provides ophthalmologists with therapeutic laser solutions to treat the four main causes of blindness: glaucoma, cataracts, diabetic retinopathy and macular degeneration.

Lumibird Medical is the medical holding of the Lumibird Group, a company invoolvled in the development of solid-state lasers for scientific and industrial use. It comprises Quantel Medical (France and Polska) and Ellex (Australia, Japan and United States), since July 2020, along with Optotek Medical in Slovenia and Lumibird Medical Nordics (Sweden, Finland and Norway)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.